Abstract:Extracellular beta-amyloid (A beta) deposition and intraneuronal phosphorylated-tau (pTau) accumulation are the hallmark lesions of Alzheimer's disease (AD). Recently, "sorfra" plaques, named for the extracellular deposition of sortilin c-terminal fragments, are reported as a new AD-related proteopathy, which develop in the human cerebrum resembling the spatiotemporal trajectory of tauopathy. Here, we identified intraneuronal sortilin aggregation as a change related to the development of granulovacuolar degeneration (GVD), tauopathy, and sorfra plaques in the human hippocampal formation. Intraneuronal sortilin aggregation occurred as cytoplasmic inclusions among the pyramidal neurons, co-labeled by antibodies to the extracellular domain and intracellular C-terminal of sortilin. They existed infrequently in the brains of adults, while their density as quantified in the subiculum/CA1 areas increased in the brains from elderly lacking A beta/pTau, with pTau (i.e., primary age-related tauopathy, PART cases), and with A beta/pTau (probably/definitive AD, pAD/AD cases) pathologies. In PART and pAD/AD cases, the intraneuronal sortilin aggregates colocalized partially with various GVD markers including casein kinase 1 delta (Ck1 delta) and charged multivesicular body protein 2B (CHMP2B). Single-cell densitometry established an inverse correlation between sortilin immunoreactivity and that of Ck1 delta, CHMP2B, p62, and pTau among pyramidal neurons. In pAD/AD cases, the sortilin aggregates were reduced in density as moving from the subiculum to CA subregions, wherein sorfra plaques became fewer and absent. Taken together, we consider intraneuronal sortilin aggregation an aging/stress-related change implicating protein sorting deficit, which can activate protein clearance responses including via enhanced phosphorylation and hydrolysis, thereby promoting GVD, sorfra, and Tau pathogenesis, and ultimately, neuronal destruction and death.

Reduction of Sortilin-1 in Alzheimer Hippocampus and in Cytokine-Stressed Human Brain Cells

Sortilin Inhibits Amyloid Pathology by Regulating Non-Specific Degradation of APP.

Intraneuronal sortilin aggregation relative to granulovacuolar degeneration, tau pathogenesis and sorfra plaque formation in human hippocampal formation

A Study of the SORL1 Gene in the Pathogenesis of Late-onset Alzheimer’s Disease by Affecting the Expression of BDNF

The Alzheimer's disease gene SORL1 regulates lysosome function in human microglia

Snx27 and Sorla Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein

SORLA Attenuates EphA4 Signaling and Amyloid Β–induced Neurodegeneration

Differential effects of SORL1 deficiency on the endo-lysosomal network in human neurons and microglia

Endo-Lysosomal Network Disorder Reprograms Energy Metabolism in SorL1-Null Rat Hippocampus

The Role of SORL1 in Alzheimer’s Disease

Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease

Sortilin: a New Player in Dementia and Alzheimer-type Neuropathology

Lack of Human-Like Extracellular Sortilin Neuropathology in Transgenic Alzheimer’s Disease Model Mice and Macaques

Impact of SORL1 Genetic Variations on MRI Markers in Non-Demented Elders.

Sortilin C-terminal fragment deposition depicts tangle-related nonamyloid neuritic plaque growth in Alzheimer’s disease

Extracellular Sortilin Proteopathy Relative to β-Amyloid and Tau in Aged and Alzheimer's Disease Human Brains.

Sortilin Fragments Deposit at Senile Plaques in Human Cerebrum.

Sortilin C-terminal Fragment Deposition Depicts Tangle-Related Nonamyloid Neuritic Plaque Growth in Alzheimer's Disease

Silencing of LRP1 Exacerbates Inflammatory Response Via TLR4/NF-κB/MAPKs Signaling Pathways in APP/PS1 Transgenic Mice

An NF-κB-sensitive Micro RNA-146a-mediated Inflammatory Circuit in Alzheimer Disease and in Stressed Human Brain Cells

A fragment of cell adhesion molecule L1 reduces amyloid-β plaques in a mouse model of Alzheimer’s disease